Modulus, a cell therapy biotech incubated at the Allen Institute for AI, raises $3.5M

18 Jul, 2021

Modulus, a cell therapy biotech incubated at the Allen Institute for AI, raises $3.5M
Photo by Harmen Jelle van Mourik on Unsplash

– Modulus Therapeutics, a Seattle-based cellular therapy company, raised $3.5m in seed funding.
– The company combines laboratory research with machine learning to engineer immune cells with enhanced anti-tumor powers.
– Modulus focuses on generating performance-enhancing genetic changes in natural killer (NK) cells, an up-and-coming immune cell type in the cell therapy field.
– The company is building a platform that could potentially provide early cell product candidates to more mature cellular therapy companies for further testing.

Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: